Bulletin
Investor Alert

Biotech Stocks Archives | Email alerts

June 29, 2010, 3:41 p.m. EDT

China jitters weigh on drug stocks; Javelin rockets

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Dow Jones Industrial Average (DJIA)

or Cancel Already have a watchlist? Log In

By Val Brickates Kennedy, MarketWatch

BOSTON (MarketWatch) -- Investor jitters over the state of the Chinese economy weighed on both the broader market and the drug sector Tuesday afternoon.

The NYSE Arca Pharmaceutical Index declined 1.7% to 274.86, and the NYSE Arca Biotechnology Index fell 3.6% to 1,035.87. The Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA +1.27% tumbled almost 300 points to rest at 9,845, largely over concerns that China's economic recovery was fizzling.

Javelin Pharmaceuticals broke sharply from the downward trend, with shares rocketing almost 60% to $2.18.

Late Monday, Hospira Inc. said that it plans to complete its tender offer of $2.20 a share for Javelin's stock by the end of the month. The deal had been stalled over Hospira's concerns about a recent recall of Javelin's pain medication Dyloject in the U.K. The product is awaiting approval in the U.S.

Earlier this month, Javelin sued to compel Hospira to follow through on their merger agreement, under which Hospira had also agreed to loan Javelin $2 million on June 1. Hospira has since agreed to fund the loan.

PSivida Corp. and partner Alimera Sciences /zigman2/quotes/205266417/composite ALIM -0.59% were also in the spotlight on news that Alimera has submitted a market application for U.S. regulatory approval of their ophthalmology product Iluvien, a treatment for diabetic macular edema. The condition is a leading cause of vision loss.

Alimera has also requested that Iluvien be granted priority review by the U.S. Food and Drug Administration, meaning that the agency could issue a decision on the product during the fourth quarter.

PSivida was up 1% in afternoon trading after climbing 8% earlier in the session. Alimera shares also jumped 8% before reversing course later in the day. Alimera's stock was lately down 6% at $7.60.

/zigman2/quotes/210598065/realtime
US : Dow Jones Global
33,761.05
+424.38 +1.27%
Volume: 320.97M
Aug. 12, 2022 6:27p
loading...
/zigman2/quotes/205266417/composite
US : U.S.: Nasdaq
$ 6.73
-0.04 -0.59%
Volume: 10,651
Aug. 12, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$47.13 million
Rev. per Employee
$341,649
loading...

Val Brickates Kennedy is a reporter for MarketWatch in Boston.

This Story has 0 Comments
Be the first to comment
More News In
Markets

Story Conversation

Commenting FAQs »

Partner Center

World News from MarketWatch

Link to MarketWatch's Slice.